Literature DB >> 15934322

Probability prediction in multistate survival models for patients with chronic myeloid leukaemia.

Ya Fang1, Putter Hein.   

Abstract

In order to find an appropriate model suitable for a multistate survival experiment, 634 patients with chronic myeloid leukaemia (CML) were selected to illustrate the method of analysis. After transplantation, there were 4 possible situations for a patient: disease free, relapse but still alive, death before relapse, and death after relapse. The last 3 events were considered as treatment failure. The results showed that the risk of death before relapse was higher than that of the relapse, especially in the first year after transplantation with competing-risk method. The result of patients with relapse time less than 12 months was much poor by the Kaplan-Meier method. And the multistate survival models were developed, which were detailed and informative based on the analysis of competing risks and Kaplan-Meier analysis. With the multistate survival models, a further analysis on conditional probability was made for patients who were disease free and still alive at month 12 after transplantation. It was concluded that it was possible for an individual patient to predict the 4 possible probabilities at any time. Also the prognoses for relapse either death or not and death either before or after relapse may be given. Furthermore, the conditional probabilities for patients who were disease free and still alive in a given time after transplantation can be predicted.

Entities:  

Mesh:

Year:  2005        PMID: 15934322     DOI: 10.1007/BF02831400

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  7 in total

1.  Optimizing treatment for chronic myeloid leukemia.

Authors:  J M Goldman
Journal:  N Engl J Med       Date:  1997-07-24       Impact factor: 91.245

2.  Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?

Authors:  M S Pepe; M Mori
Journal:  Stat Med       Date:  1993-04-30       Impact factor: 2.373

3.  Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation.

Authors:  A Gratwohl; J Hermans; D Niederwieser; F Frassoni; W Arcese; G Gahrton; G Bandini; E Carreras; J P Vernant; A Bosi
Journal:  Bone Marrow Transplant       Date:  1993-11       Impact factor: 5.483

4.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  A Gratwohl; J Hermans; J M Goldman; W Arcese; E Carreras; A Devergie; F Frassoni; G Gahrton; H J Kolb; D Niederwieser; T Ruutu; J P Vernant; T de Witte; J Apperley
Journal:  Lancet       Date:  1998-10-03       Impact factor: 79.321

5.  Relapse risk assessment of transplantation for patients with chronic myeloid leukaemia.

Authors:  Ya Fang; Alois Gratwohl; Hans C van Houwelingen
Journal:  Chin Med J (Engl)       Date:  2003-02       Impact factor: 2.628

6.  Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program.

Authors:  T Sasazuki; T Juji; Y Morishima; N Kinukawa; H Kashiwabara; H Inoko; T Yoshida; A Kimura; T Akaza; N Kamikawaji; Y Kodera; F Takaku
Journal:  N Engl J Med       Date:  1998-10-22       Impact factor: 91.245

7.  Plotting summary predictions in multistate survival models: probabilities of relapse and death in remission for bone marrow transplantation patients.

Authors:  J P Klein; N Keiding; E A Copelan
Journal:  Stat Med       Date:  1993-12-30       Impact factor: 2.373

  7 in total
  1 in total

1.  The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions?

Authors:  Joshua F Zeidner; Marianna Zahurak; Gary L Rosner; Christopher D Gocke; Richard J Jones; B Douglas Smith
Journal:  Leuk Lymphoma       Date:  2014-06-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.